In the actual human clinical safety and effectiveness test, we can observe the immunohistochemical expression of HDAC in clinical work and combine with traditional glioma gene diagnosis to analyze and judge the prognosis of glioma diseases. This evidence concerns the gene HDAC9 and glioma.